Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma

Overview of attention for article published in JCO Precision Oncology, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 31 X users

Readers on

mendeley: 16 Mendeley

So far, Altmetric has seen 34 X posts from 31 X users, with an upper bound of 148,906 followers.

RT @BradMcG04: Just published in @JCOPO_ASCO "Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients W…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 30 additional X posts.